Supplemental Parenteral Nutrition in Critically Ill Adults: A Pilot Randomised Controlled Trial
NCT ID: NCT01847534
Last Updated: 2016-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
100 participants
INTERVENTIONAL
2014-02-28
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Whilst nutrition is essential for recovery, there are several issues with the delivery of nutrition via the stomach (the most commonly used method of delivering nutrition in the critically ill). For many reasons, patients are unable to tolerate large quantities of nutrition via the stomach and in addition to this there are hospital or procedural reasons for nutrition being turned off for lengthy periods of time. As such, this results in patients being delivered only about half of the nutrition that is planned. One potential way to overcome this is to deliver nutrition via the vein, whilst nutrition into the stomach continues, with the aim to meet the energy gap that is lost by inadequate nutrition via the stomach.
In this study of 100 patients, we will deliver combined nutrition via the vein and stomach in 50 patients and the other 50 patients will receive nutrition as per normal practice. We will measure important outcomes for these patients to determine if this allows us to meet significantly more of their nutrition needs. This study will also help us determine how best to design a larger study of this strategy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Augmented Versus Routine Approach to Giving Energy Trial
NCT02306746
Nutrition Therapy in Adult Patients Requiring ECMO in Australia and New Zealand
NCT02048046
CONTINUation of Enteral Nutrition Prior to Extubation Compared to Standard Care
NCT06382727
Optimised Nutritional Therapy and Early Physiotherapy in Long Term ICU Patients (NutriPhyT Trial)
NCT05865314
Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients
NCT00512122
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. To determine whether the supplemental Parenteral Nutrition (PN) strategy leads to the delivery of increased amounts of total nutrition (measured as energy delivered), and is safe in regards to adverse effects.
2. To measure the clinical outcomes in patients receiving both study strategies to provide information to assist design of a larger randomized controlled trial.
Secondary objectives in a sub-set of patients are:
3. To determine whether the supplemental PN strategy leads to improved nitrogen balance.
4. To determine both the nutritional requirements and nutritional intake of critically ill patients during the period of hospitalization after transfer from the Intensive Care Unit (ICU).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard Care
Standard care: Nutrition will be managed as per best practice and local policy including the use of small bowel feeding tubes, prokinetics and PN if required to meet nutrition needs.
Standard Care
Supplemental PN
Supplemental PN to complete inadequate EN provision
1. Patients allocated to the supplemental PN (intervention) group will have PN commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation.
2. EN will be managed as per local protocol however EN must not be reduced based on the supplemental PN being administered.
3. The adequacy of nutrition provision from both PN and EN will be assessed at midday each day for 7 days or until ICU discharge. The dose of PN will be adjusted according to a prespecified schedule.
Supplemental PN
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Supplemental PN
Standard Care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted to intensive care between 48 hours and 72 hours previously
* Mechanically ventilated at the time of enrollment and expected to remain ventilated until the day after tomorrow
* At least 16 years of age
* Have central venous access suitable for PN solution administration
* Have 1 or more organ system failure (respiratory, cardiovascular or renal) related to their acute illness defined as:
1. Partial pressure of oxygen (PaO2) / Fraction of Inspired oxygen (FiO2) ratio ≤ 300 mmHg
2. Currently on 1 or more continuous vasopressor infusion which were started at least 4 hours ago at a minimum dose of :
1. Dopamine greater than 5 mcg/kg/min
2. Noradrenaline ≥ 0.1mcg/kg/min
3. Adrenaline ≥ 0.1 mcg/kg/min
4. Any dose of total vasopressin
5. Milrinone \>0.25mcg/kg/min)
3. Renal dysfunction defined as
In patients without known renal disease:
1. serum creatinine \> 171 mmol/l OR
2. Currently receiving renal replacement therapy
In patients with known renal disease:
3. an absolute increase of \> 50% in creatinine from baseline OR
4. Currently receiving renal replacement therapy
4. Currently has an intracranial pressure monitor or ventricular drain in situ
5. Currently receiving extracorporeal membrane oxygenation
6. Currently has a ventricular assist device
Exclusion Criteria
* Currently receiving PN
* Standard PN solutions cannot be delivered at enrolment (i.e. clinicians believe that a patient definitely needs a specific parenteral nutrition formulation (e.g. glutamine-supplementation or specific lipid formulation).
* Death is imminent or deemed highly likely in the next 96 hours.
* There is a current treatment limitation in place or the patient is unlikely to survive to 6 months due to underlying illness
* More than 80% of energy requirements have been satisfactorily delivered via the enteral route in the last 24 hours.
* Are known to be pregnant
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baxter Healthcare Corporation
INDUSTRY
Australian and New Zealand Intensive Care Research Centre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Alfred Hospital
Melbourne, Victoria, Australia
Geelong Hospital
Geelong, , Australia
Auckland City Hospital (CVICU)
Auckland, , New Zealand
Auckland City Hospital (DCCM)
Auckland, , New Zealand
Christchurch Hospital
Christchurch, , New Zealand
Wellington Hospital
Wellington, , New Zealand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ridley EJ, Davies AR, Parke R, Bailey M, McArthur C, Gillanders L, Cooper DJ, McGuinness S; Supplemental Parenteral Nutrition Clinical Investigators. Supplemental parenteral nutrition versus usual care in critically ill adults: a pilot randomized controlled study. Crit Care. 2018 Jan 23;22(1):12. doi: 10.1186/s13054-018-1939-7.
Ridley EJ, Davies AR, Parke R, Bailey M, McArthur C, Gillanders L, Cooper DJ, McGuinness S; Supplemental Parenteral Nutrition Clinical Investigators. Supplemental parenteral nutrition in critically ill patients: a study protocol for a phase II randomised controlled trial. Trials. 2015 Dec 24;16:587. doi: 10.1186/s13063-015-1118-y.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANZIC RC AD 003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.